
News|Articles|January 27, 2005
Warning Letter
Warning Letter
Advertisement
In a 7 January
As is typical in these warnings, the agency voicedconcerns that Essential is compounding not for individual patients butfor third-party resale, and that the compounded drugs duplicateapproved products in dosage and concentration.
Douglas McCormick
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Renewing Prosaic Generics for Cancer Treatment
2
Viral Safety 2.0: Plant-Ready Actions for ICH Q5A(R2) Compliance
3
Leveraging an Innovative Mid-Scale Manufacturing Solution to Meet Diverse Needs
4
Faster Doesn’t Mean Easier: Development Impacts of a New Biosimilar Regulatory Landscape
5




